Skip to main content
. 2020 Jan 3;17(4):430–432. doi: 10.1038/s41423-019-0355-5

Fig. 1. Response and toxicities after the patient received the CAR T-38 cell treatment.

Fig. 1

a Schematic of the clinical protocol. A, cytosine arabinoside; CTX, cyclophosphamide; Dex, dexamethasone; F, fludarabine; P, methylprednisolone; V, vindesine. b, c Response in BM on day 13 and in PB on day 18. Numbers represent the percentage of positive cells. The gating strategy is shown in Fig. S5a. d The change in the percentage of CD38+ B-ALL cells in PB and BM before (on day 0) and after CAR T-38 cell infusion (PB on day 18 and BM on day 13). e The CAR gene copy number in the genomic DNA in BM analyzed using Q-PCR. f Persistence of infused CAR T-38 cells in PB. The blue line indicates the CAR gene copy number in the genomic DNA detected by Q-PCR, and the red line indicates the number of CAR T-38 cells per microliter (μL) PB by flow cytometry. g, h CD38 expression on mononuclear cells and granulocytes in PB on days 0 and 18 and in BM on days 0 and 13. The gating strategies are shown in Fig. S5b, c. i The patient suffered from transient liver damage that was accompanied by an elevation in aspartate aminotransferase (AST, blue line) and alanine aminotransferase (ALT, red line) 9 days after the CAR T-38 cell infusion. The dotted black line indicates the normal maximum levels of ALT and AST. j A CT scan showed that the patient had diffuse damage in both lungs, mainly including interstitial exudation, 13 days after the CAR T-38 cell infusion. k Variation in the serum levels of ferritin (red line) and C-reactive protein (CRP, blue line) in PB after the infusion of CAR T-38 cells. Multiple cycles of tocilizumab, etanercept, infliximab, and steroids, including methylprednisolone and dexamethasone, were subsequently administered, and their detailed doses are presented in Fig. S4. * indicates that the serum ferritin level was outside the maximum range (>2000 ng/mL) 4 days after the CAR T-38 cell infusion. l Changes in the serum IL-2, IL-6, IL-8, IL-10 and TNF-α levels in PB after CAR T-38 cell infusion. # indicates that the serum IL-2 level was outside the maximum range (>7500 ng/mL) 7 days after the cell infusion.